充血性心力衰竭 - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Abstract

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T
AIM2-driven inflammasome activation in heart failure
Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF
Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Left Ventricular Assist Devices: Synergistic Model Between Technology and Medicine
Association of loop diuretics use and dose with outcomes in outpatients with heart failure: a systematic review and meta-analysis of observational studies involving 96,959 patients
SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials

Original Research

16 Sep 2019

JOURNAL：Circulation.

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Nassif ME, Windsor S, DEFINE-HF Investigators.

10666

Keywords: SGLT-2 inhibitors; HFrEF; T2DM; Dapagliflozin effect

FULL TEXT PDF